Pharmaceutical Tickers $NURO, $DRIO, $ORGS, and $DMAC Surge +23.55% in Weekly Performance
Tickers in the industry - $CRON, $TLRY, $CGC, $ACB
Robots for this industry :
Swing trader: Deep Trend Analysis v.2 (TA) - 30-day Annualized Return +21%
Swing trader: Top High-Volatility Stocks v.2 (TA) - 30-day Annualized Return +20%
Over the past week, the pharmaceutical sector has emerged as a standout performer, with an astonishing +23.55% increase in performance. This surge in the pharmaceutical industry has captured the attention of both seasoned investors and newcomers alike. In this article, we will delve into the details of this theme, focusing on four key tickers: NURO, DRIO, ORGS, and DMAC.
A Positive Outlook Supported by the MA50MA10 Indicator
One of the primary indicators of the positive outlook for these pharmaceutical stocks is the MA50MA10 Indicator. This indicator suggests that market sentiment is favorable for these companies. Moreover, Tickeron, a reputable source for market predictions, shares this positive sentiment, forecasting a potential increase of more than 4.00% in the next month with a likelihood of 68%. This optimistic outlook has piqued the interest of investors seeking growth opportunities in the pharmaceutical sector.
Strong 15 Indicator Trends
The 15 indicator, a widely followed technical indicator, confirms the bullish sentiment for three stocks in this group. These stocks are exhibiting a similar positive trend, with an average likelihood of success standing at an impressive 83%. This aligns with the overall positive sentiment surrounding the pharmaceutical sector.
Notable Companies
Within this group, some pharmaceutical companies stand out as particularly noteworthy:
-
Tilray Brands (TLRY): TLRY is a significant player in the pharmaceutical industry and is listed on the NASDAQ. It boasts the highest market capitalization in this group, valued at a substantial $2.2 billion.
-
Canopy Growth Corp (CGC): CGC is another prominent player on the NASDAQ and has been making waves. It experienced remarkable price growth, rising by an impressive 69.42% over a specific period.
-
Aurora Cannabis (ACB): ACB, also listed on the NASDAQ, demonstrated a strong performance, gaining 16.06% within a defined timeframe.
Market Cap Variation
The market capitalization within the pharmaceutical theme varies significantly, with an average of approximately $922 million. Among the four tickers, TLRY holds the highest valuation at $2.2 billion, showcasing its dominance in the industry. On the other end of the spectrum, ACB is the lowest valued company in this group, with a market capitalization of $184.3 million. This diverse range of market caps highlights the multitude of investment opportunities available within the pharmaceutical sector.
Price Performance and Notable News
The price performance of these pharmaceutical stocks has been remarkable. On a weekly basis, the average price growth across all stocks in this theme was an impressive 23.55%, demonstrating significant short-term potential. Moreover, the average monthly price growth stood at 32.48%, indicating consistent growth over a slightly longer horizon. However, it's essential to note that the average quarterly price growth was -11%, indicating potential volatility in the longer term. CGC stood out as the top performer in terms of weekly price growth, surging by an impressive 69.42%.
Volume Fluctuations
The analysis of volume fluctuations provides insight into investor interest and activity in these pharmaceutical stocks. On a weekly basis, the average volume growth across all stocks in this theme was a significant 66.58%, signaling heightened investor interest. Moreover, the average monthly and quarterly volume growth figures were even more impressive, at 268.01% and 533.34%, respectively. This indicates a strong and sustained interest in pharmaceutical stocks.
Key Ticker Analysis
Let's explore the trends of three key tickers within this pharmaceutical theme:
-
CRON: CRON exhibited a notable upward trend as its 10-day moving average crossed above the 50-day moving average on September 07, 2023. This shift is often considered a buy signal, with an 86% probability of continued upward movement. The stock showed a significant uptrend during the month of 08/08/23 - 09/08/23, with a growth rate of +26% during that period.
-
TLRY: TLRY's Moving Average Convergence Divergence (MACD) turned positive on September 01, 2023. Historically, when TLRY's MACD turned positive, the stock continued to rise in 89% of cases over the following month. TLRY has demonstrated a consistent uptrend, particularly during the week of 08/31/23 - 09/08/23, with a growth rate of +2%.
-
CGC: CGC witnessed a positive shift in its Momentum Indicator on August 29, 2023, indicating a potential new upward trend. Historically, when this indicator turned positive, the stock moved higher in 81% of cases. CGC has experienced a remarkable uptrend, particularly during the month of 08/08/23 - 09/08/23, with a growth rate of +99%.
In summary, the pharmaceutical sector has experienced a significant surge in performance, driven by positive indicators and strong price growth. Investors should closely monitor these stocks, particularly CRON, TLRY, and CGC, as they exhibit strong potential for further growth. However, it's crucial to remain vigilant and conduct thorough research when considering investment decisions in this dynamic sector.
Contributor
TLRY's RSI Indicator climbs out of oversold territory
The RSI Indicator for TLRY moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 39 of the 47 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
TLRY moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TLRY crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.368) is normal, around the industry mean (43.873). P/E Ratio (8.518) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement